- Home
- TCBX vs ARVN Comparison
TCBX vs ARVN Comparison
Compare TCBX & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBX
- ARVN
- Stock Information
- Founded
- TCBX 2008
- ARVN 2015
- Country
- TCBX United States
- ARVN United States
- Employees
- TCBX N/A
- ARVN N/A
- Industry
- TCBX Banks
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- TCBX Finance
- ARVN Health Care
- Exchange
- TCBX Nasdaq
- ARVN Nasdaq
- Market Cap
- TCBX 481.8M
- ARVN 456.2M
- IPO Year
- TCBX 2021
- ARVN 2018
- Fundamental
- Price
- TCBX $39.59
- ARVN $7.62
- Analyst Decision
- TCBX Hold
- ARVN Buy
- Analyst Count
- TCBX 4
- ARVN 22
- Target Price
- TCBX $39.00
- ARVN $20.21
- AVG Volume (30 Days)
- TCBX 57.9K
- ARVN 1.4M
- Earning Date
- TCBX 10-22-2025
- ARVN 10-29-2025
- Dividend Yield
- TCBX N/A
- ARVN N/A
- EPS Growth
- TCBX 52.43
- ARVN N/A
- EPS
- TCBX 3.28
- ARVN N/A
- Revenue
- TCBX $182,318,000.00
- ARVN $372,800,000.00
- Revenue This Year
- TCBX $23.66
- ARVN $4.87
- Revenue Next Year
- TCBX $6.46
- ARVN N/A
- P/E Ratio
- TCBX $12.10
- ARVN N/A
- Revenue Growth
- TCBX 20.25
- ARVN 299.57
- 52 Week Low
- TCBX $24.87
- ARVN $5.90
- 52 Week High
- TCBX $41.25
- ARVN $29.61
- Technical
- Relative Strength Index (RSI)
- TCBX 56.51
- ARVN 50.66
- Support Level
- TCBX $39.08
- ARVN $7.58
- Resistance Level
- TCBX $40.02
- ARVN $8.23
- Average True Range (ATR)
- TCBX 0.90
- ARVN 0.38
- MACD
- TCBX -0.16
- ARVN 0.01
- Stochastic Oscillator
- TCBX 27.83
- ARVN 35.11
About TCBX Third Coast Bancshares Inc.
Third Coast Bancshares Inc is a bank holding company. It focuses on providing commercial banking solutions to small and medium-sized businesses and professionals with operations in its markets. The bank operates eleven branches in the Greater Houston, Dallas-Fort Worth, and Austin-San Antonio markets, and one branch in Detroit, Texas. The company operates through one segment, community banking, It generates the majority of its revenue from interest on loans, customer service, and loan fees.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.